Since 2014, Dr Luc Otten is founder and manager officer of Otten Life Sciences Consulting, a Lausanne-based consulting company which provides services for financial due diligence and executive assignment in Life Sciences.
Between 2014 and 2019, he was COO at Phi Pharma SA, a Swiss-based biotech company specialised in the discovery and early clinical development of peptide drug conjugate in oncology and infectious diseases. Between 2010 and 2015, he was principal in the field of life sciences at Vinci Capital (now Renaissance), a leading Swiss private equity fund manager company. Between 2008 and 2010, he was equity research analyst (biotech and pharma) at Helvea – a leading Swiss brokerage company. In 2005, he co-received the Histiocytosis Research Trust Grant for the first genetic animal model of histiocytosis. His research focused on oncology, immunology and gene regulation (22 peer-reviewed publications). He studied Medicine in Geneva and holds a doctorate in Medicine and Biology from the University of Geneva. Dr. Otten also holds a Certificate of Advanced Studies in Biotech Management, Medtech and Pharma Ventures from EPFL and trained in biostatistics for clinical research at the University of Geneva.
Otten Life Sciences Consulting Sàrl
Route de la Corniche 5